Anti-BNIP3 Antibody, clone 1G21 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1G21 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3). It targets an epitope within 18 amino acids from the N-terminal half.

KLH-conjugated linear peptide corresponding to 18 amino acids from the N-terminal half of human of human BNIP3.

Quality Control Testing

Evaluated by Western Blotting in Jurkat cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected BNIP3 in Jurkat cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected BNIP3 in Human kidney tissue lysate and 1:10,000 dilution detected His/ABP-tagged recombinant fragment of Human BNIP3.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected BNIP3 in Human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound BNIP3 with a KD of 7.9 x 10-8 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected BNIP3 in U2OS cells.

Enzyme Immunoassay (ELISA) Analysis: A serial dilutions from a representative lot detected His/ABP-tagged recombinant fragment of Human BNIP3.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (UniProt: Q12983; also known as BNIP3) is encoded by the BNIP3 gene (Gene ID: 664) in human. BNIP3 is an atypical member of the BCL-2 family and the pro-apoptotic BH3-only protein subfamily. Its N-terminal region contains a PEST domain, a BH3 domain (aa 100-125) and a conserved domain. The C-terminal region includes four major domains and involved in protein-protein interactions. The transmembrane domain (aa 164-184) allows for dimerization and insertion into membranes to elicit cell death. The function of BNIP3 ranges from differentiation, growth, maturation, proliferation, stress responses, activates mitochondrial autophagy and initiating numerous forms of cell death through various pathways. It may play context- and cell-type specific roles. BNIP3 expression is widespread in various tissues, including the heart, skeletal muscle, liver, and brain. Its expression is often upregulated under conditions of cellular stress, such as hypoxia (low oxygen levels), ischemia-reperfusion injury, or nutrient deprivation. Dysregulation of BNIP3 expression has been observed in a range of cancers. BNIP3 has also been associated with cardiac diseases, including heart failure and myocardial infarction. Additionally, BNIP3 has been implicated in neurodegenerative diseases, such as Parkinson′s disease. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Field, J T., and Gordon, JW. (2022). Biochim. Biophys. Acta Mol. Cell Res.1869(10); 119325; .Zhang, T., et al., (2016), J. Biol. Chem. 291(41); 21616-21629).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.